| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Kuwanon E targets multiple enzymes and pathways. It has cytotoxic activity against leukemic cells and inhibits cholinesterase enzymes (AChE and BChE). It also reduces the level of the pro-inflammatory cytokine IL-1β. Its anticancer and anti-inflammatory activities are of particular interest.
|
|---|---|
| ln Vitro |
In vitro, Kuwanon E exhibits cytotoxic activity against THP-1 human monocytic leukemic cells, with an IC₅₀ of 4.0 µM. It inhibits AChE and BChE in a dose-dependent manner, with Ki values ranging from 3.1 to 37.5 µM and 1.7 to 19.1 µM, respectively. It also reduces the level of IL-1β.
|
| ln Vivo |
In vivo, the cytotoxic and anti-inflammatory activities of Kuwanon E suggest potential for cancer and inflammatory disease research. Its ability to inhibit cholinesterase enzymes suggests potential for neurological research. However, specific in vivo efficacy data are not detailed in the provided search results.
|
| Enzyme Assay |
In vitro non-cell enzyme assays for Kuwanon E typically involve measuring its inhibition of AChE and BChE activities. The compound is incubated with the enzyme and a chromogenic substrate (e.g., Ellman's reagent), and the inhibition of activity is measured. Ki values are determined from kinetic analysis.
|
| Cell Assay |
In vitro cell-based assays for Kuwanon E use THP-1 human monocytic leukemic cells to study its cytotoxic effects. Cells are treated with the compound, and cell viability is assessed using MTT or similar assays. Its effects on IL-1β production can be measured in stimulated immune cells by ELISA.
|
| Animal Protocol |
In vivo animal studies for Kuwanon E would likely employ xenograft models using THP-1 cells to study its anti-leukemic activity. Its anti-inflammatory effects could be studied in models of inflammation, where IL-1β levels are measured.
|
| ADME/Pharmacokinetics |
Kuwanon E has a molecular weight of 424.48 g/mol and a molecular formula of C₂₅H₂₈O₆. It is a flavonoid. It is a solid and should be stored at 2-8°C for up to 24 months. It is soluble in organic solvents. Detailed pharmacokinetic data are not widely published.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Kuwanon E is not extensively detailed in the provided search results. As a natural flavonoid, it is generally considered to have a good safety profile, but comprehensive toxicological studies are needed. It is not intended for human therapeutic use without further development.
|
| References | |
| Additional Infomation |
It has been reported that mulberry (Morus alba) contains Kuwanon E, and relevant data is available for reference.
Kuwanon E is a flavonoid from Morus alba with cytotoxic activity against leukemic cells (IC₅₀ = 4.0 µM) and cholinesterase inhibitory activity. It also reduces IL-1β levels. It is not approved for clinical use and is intended for research purposes only. |
| Molecular Formula |
C25H28O6
|
|---|---|
| Molecular Weight |
424.4862
|
| Exact Mass |
424.188
|
| CAS # |
68401-05-8
|
| PubChem CID |
10342292
|
| Appearance |
Off-white to light brown solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
678.3±55.0 °C at 760 mmHg
|
| Melting Point |
132 - 136 °C
|
| Flash Point |
232.0±25.0 °C
|
| Vapour Pressure |
0.0±2.2 mmHg at 25°C
|
| Index of Refraction |
1.629
|
| LogP |
6.6
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
31
|
| Complexity |
682
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(=CCC/C(=C/CC1=CC(=C(C=C1O)O)C2CC(=O)C3=C(C=C(C=C3O2)O)O)/C)C
|
| InChi Key |
GJFHZVPRFLHEBR-VIZOYTHASA-N
|
| InChi Code |
InChI=1S/C25H28O6/c1-14(2)5-4-6-15(3)7-8-16-9-18(20(28)12-19(16)27)23-13-22(30)25-21(29)10-17(26)11-24(25)31-23/h5,7,9-12,23,26-29H,4,6,8,13H2,1-3H3/b15-7+
|
| Chemical Name |
2-[5-[(2E)-3,7-dimethylocta-2,6-dienyl]-2,4-dihydroxyphenyl]-5,7-dihydroxy-2,3-dihydrochromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3558 mL | 11.7788 mL | 23.5577 mL | |
| 5 mM | 0.4712 mL | 2.3558 mL | 4.7115 mL | |
| 10 mM | 0.2356 mL | 1.1779 mL | 2.3558 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
